|
TTC21B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69608771471985E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.05102601569251E-12 |
| Normal-vs-Stage2 |
5.75495207044696E-12 |
| Normal-vs-Stage3 |
1.90958360235527E-14 |
| Normal-vs-Stage4 |
1.65201186064223E-12 |
| Stage1-vs-Stage2 |
2.925600E-01 |
| Stage1-vs-Stage3 |
1.326620E-01 |
| Stage1-vs-Stage4 |
1.021580E-01 |
| Stage2-vs-Stage3 |
9.651200E-01 |
| Stage2-vs-Stage4 |
8.430800E-01 |
| Stage3-vs-Stage4 |
8.420200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.68165481539972E-12 |
| Normal-vs-AfricanAmerican |
5.95349999999994E-05 |
| Normal-vs-Asian |
2.60279575670097E-11 |
| Caucasian-vs-AfricanAmerican |
2.263900E-02 |
| Caucasian-vs-Asian |
6.752200E-01 |
| AfricanAmerican-vs-Asian |
8.376400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66922031752392E-12 |
| Normal-vs-Female |
1.72872827164383E-12 |
| Male-vs-Female |
5.520400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00497388189069E-12 |
| Normal-vs-Age(41-60Yrs) |
2.1538326677728E-14 |
| Normal-vs-Age(61-80Yrs) |
1.72195591119362E-13 |
| Normal-vs-Age(81-100Yrs) |
7.8838000000081E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.565230E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.111200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.114400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.818400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.208600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.877800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.041790E-01 |
| Classical-VS-Follicular |
3.351200E-01 |
| Classical-VS-Other |
4.298600E-01 |
| Classical-VS-Normal |
5.13022957449039E-12 |
| Tall-VS-Follicular |
3.948600E-01 |
| Tall-VS-Other |
9.667800E-01 |
| Tall-VS-Normal |
1.68187686000465E-12 |
| Follicular-VS-Other |
7.319200E-01 |
| Follicular-VS-Normal |
1.73128178460047E-12 |
| Other-VS-Normal |
3.966900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64546154479694E-12 |
| Normal-vs-N1 |
5.06039654624146E-13 |
| N0-vs-N1 |
6.702800E-01 |
|
|
